BioWorld Science, Infection

RSS

Dura obtains marketing rights of Lilly's cephalosporin antibiotics

Aug. 30, 1996

Erythromycin A 9-O-oxime derivatives from Zambon

Aug. 23, 1996

SR-3775: Promising candidate for cytomegalovirus disease treatment

Aug. 23, 1996

GEM-132 enters phase I safety and pharmacokinetic trial

Aug. 23, 1996

SmithKline Beecham describes protease inhibitors

Aug. 23, 1996

Isis now fully owns fomivirsen

Aug. 23, 1996

Solvay to copromote Famvir in U.S.

Aug. 23, 1996

Sequus and Torrex Pharma sign Amphotec marketing agreement

Aug. 23, 1996

Xoma granted permission to commence phase III for rBPI21

Aug. 23, 1996

Parke-Davis and Xenova begin evaluation of novel antibacterial

Aug. 23, 1996